215 related articles for article (PubMed ID: 35305591)
21. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
22. Microarray-based data mining reveals key genes and potential therapeutic drugs for Cadmium-induced prostate cell malignant transformation.
Xiang Y; Zhang L; Huang Y; Ling J; Zhuo W
Environ Toxicol Pharmacol; 2019 May; 68():141-147. PubMed ID: 30897525
[TBL] [Abstract][Full Text] [Related]
23. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
[TBL] [Abstract][Full Text] [Related]
24. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.
Kobayashi A; Okuda H; Xing F; Pandey PR; Watabe M; Hirota S; Pai SK; Liu W; Fukuda K; Chambers C; Wilber A; Watabe K
J Exp Med; 2011 Dec; 208(13):2641-55. PubMed ID: 22124112
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.
Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S
Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091
[TBL] [Abstract][Full Text] [Related]
26. Bioinformatics analysis identified hub genes in prostate cancer tumorigenesis and metastasis.
Gu P; Yang D; Zhu J; Zhang M; He X
Math Biosci Eng; 2021 Apr; 18(4):3180-3196. PubMed ID: 34198380
[TBL] [Abstract][Full Text] [Related]
27. Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.
Quayle L; Ottewell PD; Holen I
Curr Cancer Drug Targets; 2015; 15(6):469-80. PubMed ID: 25968899
[TBL] [Abstract][Full Text] [Related]
28. The biology and clinical implications of prostate cancer dormancy and metastasis.
Morrissey C; Vessella RL; Lange PH; Lam HM
J Mol Med (Berl); 2016 Mar; 94(3):259-65. PubMed ID: 26489605
[TBL] [Abstract][Full Text] [Related]
29. Microarray Analysis of Novel Genes Involved in Nasopharyngeal Carcinoma.
Wang B; Wang W; Wang H; Liu W
Bull Exp Biol Med; 2021 Mar; 170(5):658-664. PubMed ID: 33788105
[TBL] [Abstract][Full Text] [Related]
30. [Screening of cell cycle-related genes regulated by KIAA0101 in gastric cancer].
Wang Z; Dang C; Yan R; Zhang H; Yuan D; Li K
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1151-1158. PubMed ID: 30377125
[TBL] [Abstract][Full Text] [Related]
31. MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer.
Schulze A; Oshi M; Endo I; Takabe K
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143224
[No Abstract] [Full Text] [Related]
32. Bioinformatics screening of biomarkers related to liver cancer.
Wang YC; Tian ZB; Tang XQ
BMC Bioinformatics; 2021 Oct; 22(Suppl 3):521. PubMed ID: 34696748
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of MAD2L1 mediated by ncRNA axis is associated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma: A review.
Liu S; Miao M; Kang L
Medicine (Baltimore); 2023 Jan; 102(2):e32625. PubMed ID: 36637946
[TBL] [Abstract][Full Text] [Related]
34.
Umbreen S; Banday MM; Jamroze A; Mansini AP; Ganaie AA; Ferrari MG; Maqbool R; Beigh FH; Murugan P; Morrissey C; Corey E; Konety BR; Saleem M
Mol Cancer Ther; 2019 Nov; 18(11):2111-2123. PubMed ID: 31467179
[TBL] [Abstract][Full Text] [Related]
35. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.
Chakrabarti R; Robles LD; Gibson J; Muroski M
Cancer Genet Cytogenet; 2002 Dec; 139(2):115-25. PubMed ID: 12550771
[TBL] [Abstract][Full Text] [Related]
36. Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer.
Fujimura T; Takahashi S; Urano T; Takayama K; Sugihara T; Obinata D; Yamada Y; Kumagai J; Kume H; Ouchi Y; Inoue S; Homma Y
Clin Cancer Res; 2014 Sep; 20(17):4625-35. PubMed ID: 24987058
[TBL] [Abstract][Full Text] [Related]
37. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.
Shiozawa Y; Berry JE; Eber MR; Jung Y; Yumoto K; Cackowski FC; Yoon HJ; Parsana P; Mehra R; Wang J; McGee S; Lee E; Nagrath S; Pienta KJ; Taichman RS
Oncotarget; 2016 Jul; 7(27):41217-41232. PubMed ID: 27172799
[TBL] [Abstract][Full Text] [Related]
38. MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1.
Li Y; Bai W; Zhang J
Biomed Pharmacother; 2017 Aug; 92():1038-1044. PubMed ID: 28609841
[TBL] [Abstract][Full Text] [Related]
39. Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer.
Meng F; Han X; Min Z; He X; Zhu S
Aging (Albany NY); 2021 Jul; 13(13):17442-17461. PubMed ID: 34229299
[TBL] [Abstract][Full Text] [Related]
40. miR-93-5p may be an important oncogene in prostate cancer by bioinformatics analysis.
Yang Y; Jia B; Zhao X; Wang Y; Ye W
J Cell Biochem; 2019 Jun; 120(6):10463-10483. PubMed ID: 30582208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
